GlassScriptPhysician profile
Daniel Joseph De Gala
NPI 1558892612
$3,426.72
in general payments reported to CMS, 2019-2025
27 companies · $17.10 in 2025
The $17.10 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.00 · 2021: $1,560 · 2022: $1,733 · 2024: $88.86 · 2025: $17.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $848.04 | 2021-2025 | |
| Lilly USA, LLC | $288.95 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.90 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $250.36 | 2021-2022 | |
| Novo Nordisk INC | $183.97 | 2021-2022 | |
| Mylan Specialty L.P. | $178.74 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $160.77 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $160.73 | 2021 | |
| Astellas Pharma US INC | $153.25 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $148.62 | 2021-2022 | |
| Glaxosmithkline, LLC. | $140.81 | 2020-2022 | |
| Amgen INC. | $139.56 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $118.46 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $86.94 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.21 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.78 | 2021 | |
| Csl Behring | $33.54 | 2024 | Kcentra |
| Esperion Therapeutics, INC. | $30.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.41 | 2021-2022 | |
| Purdue Pharma L.P. | $20.97 | 2024 | Nalmefene Hydrochloride |
| Dexcom, INC. | $17.20 | 2022 | |
| Allergan, INC. | $13.28 | 2020 | |
| Genentech USA, INC. | $13.09 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.58 | 2022 | |
| Insulet Corporation | $12.39 | 2021 | |
| Abbott Laboratories | $11.61 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel De Gala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.